Biotech

All Articles

Amgen files very first period 3 win for $400M eczema drug

.Amgen has actually discussed (PDF) the first stage 3 information on its own $400 thousand chronic e...

Biogen, UCB document phase 3 lupus succeed after failing earlier test

.Biogen and also UCB's bet one's bottom dollar improving into stage 3 on the back of a failed resear...

Aptadir wishes new RNA inhibitors may turn around difficult cancers cells

.Italian biotech Aptadir Rehabs has actually released along with the promise that its own pipeline o...

Wave surfs DMD results to regulators' doors, sending stock up

.Surge Life Sciences has satisfied its own target in a Duchenne muscular dystrophy (DMD) study, plac...

Sanofi picks brand new CSO coming from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is coming back to the pharma crease, takin...

Achilles splashes cell therapy system, prepares for cutbacks after skipping 'business viability' targets

.Achilles Rehabs has actually wrecked its own approach. The English biotech is knocking off on its c...

Aligos advertises period 2 MASH gain, lowering liver fat as much as 46%

.Aligos Rehabs is actually declaring a midstage succeed in metabolic-dysfunction affiliated steatohe...

Basilea scores $268M BARDA backing for antifungals, antibiotics

.Basilea Pharmaceutica's job developing brand new antifungals has actually obtained a considerable i...

Capricor markets Europe rights to late-stage DMD therapy for $35M

.Having already gathered up the USA civil rights to Capricor Rehabs' late-stage Duchenne muscle dyst...

FDA junks adcomm for Applied's rare ailment drug

.After dismissing the choice date for Applied Therapies' metabolic problem medication govorestat, th...